% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • mdwhittier mdwhittier Apr 2, 2014 3:35 PM Flag

    Interesting Debate

    Between bionerd51 and RNAi Analyst on their Twitter feeds. For those who have followed bionerd51 for some time, and are impressed with his grasp of the science/chemistry that Sarepta possesses, he's worthy of following on Twitter.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I would put more weight in the JPM-TMT's decision to go with Tekmira's ebola program over SRPT's than a curiously word PR.

      Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of first-in-class
      RNA-based therapeutics, announced today that its lead therapeutic drug
      candidate for the Marburg virus, AVI-7288, demonstrated up to 100%
      survival in a non-human primate (NHP) study exploring the drug's effect
      when treatment is delayed to various time points post-infection. The
      study demonstrated a significantly higher rate of survival among NHPs
      treated with AVI-7288 compared to the placebo-treated group when
      treatment was administered up to 96-hours post infection. Sarepta is
      conducting this work under a U.S. Department of Defense (DoD) contract
      managed by the Joint Project Manager Transformational Medical
      Technologies (JPM-TMT) Project Management Office, a component of the
      Joint Program Executive Office for Chemical and Biological Defense

      "These results are unprecedented and demonstrate a compelling proof of
      concept with our PMOplus(R) chemistry platform and its ability to treat
      the most lethal and fast-acting viruses, without compromising efficacy of
      survival even after up to a four-day delay in the initiation of
      treatment," said Chris Garabedian, President and Chief Executive Officer
      of Sarepta Therapeutics.

      It sounds like the 96-hour post-exposure was 100% effective but one of the other time points was only 83%.

      "This study showed a high degree of survival between 83% and 100% in each
      of four post-exposure cohorts that received daily treatments with
      AVI-7288 beginning one-, 24-, 48-, or 96-hours after infection, compared
      to 0% survival in the placebo-treated control group."

      That's an odd result.

    • You're right. Never looked before. Bionerd's on fire. Doing a good job educating over there. On his game.

13.19-0.02(-0.15%)12:10 PMEDT